# A Multi-site Expanded Access Program for MDMA-assisted Psychotherapy for Patients With Treatment-resistant PTSD

> **NCT04438512** · — · NO_LONGER_AVAILABLE · sponsor: **Resilient Pharmaceuticals**

## Conditions studied

- Post Traumatic Stress Disorder

## Interventions

- **DRUG:** Midomafetamine
- **BEHAVIORAL:** Psychotherapy

## Key facts

- **NCT ID:** NCT04438512
- **Lead sponsor:** Resilient Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** NO_LONGER_AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2024-11-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04438512

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04438512, "A Multi-site Expanded Access Program for MDMA-assisted Psychotherapy for Patients With Treatment-resistant PTSD". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04438512. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*